✦ LIBER ✦

1173 PUBLICATION Phase II trial of neo-adjuvant gemcitabine-carboplatin-paclitaxel (GCP) chemotherapy for operable non-small cell lung cancer (NSCLC)

Book ID: 122774102
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 139 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(05)81467-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PD-084 Phase II trial of gemcitabine-car

PD-084 Phase II trial of gemcitabine-carboplatin-paclitaxel (GCP) as neo-adjuvant chemotherapy for operable non-small cell lung cancer (NSCLC)

✍ Abratt, R.; Lee, J.; Han, J.; Tsai, C.; Boyer, M.; Mok, T.; Kim, S.; Lee, J.; Br 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 267 KB

Paclitaxel and carboplatin in combinatio

Paclitaxel and carboplatin in combination with gemcitabine (PCG): a phase I–II trial in non-small cell lung cancer (NSCLC)

✍ Favaretto, A; Paccagnella, A; Tumolo, S; Barbieri, F; Ceresoli, G; Gulisano, M; 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Gemcitabine and cisplatin as neo-adjuvan

Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: A phase II study

✍ Aydiner, Adnan; Kiyik, Murat; Cikrikcioglu, Saadettin; Kosar, Filiz; Gurses, Ati 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 333 KB

Paclitaxel and carboplatin in combinatio

Paclitaxel and carboplatin in combination with gemcitabine (PCG): A phase I–II trial in advanced non-small cell lung cancer (NSCLC)

✍ Ceresoli, G.L; Favaretto, A; Paccagnella, A; Barbieri, F; Bearz, A; Schiavon, A. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Weekly paclitaxel and gemcitabine chemot

Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC) : A dose-optimizing phase II trial

✍ Vera Hirsh; Renaud Whittom; Linda Ofiara; Pierre Desjardins; Joseph Ayoub; Danie 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## Abstract ## BACKGROUND The current dose‐optimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with non‐small cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity. ## METHODS

A phase II trial of Paclitaxel, Carbopla

A phase II trial of Paclitaxel, Carboplatin and Gemcitabine (Taxcarbogem) in the treatment of stage III non small cell lung cancer (NSCLC). Toxicity profile

✍ Almenarez, J; Murias, A; Garcia, I; Molano, F; Aguiar, J; Bohn, U; Camacho, M.C; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB